Core Points - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant pill vaccines using its proprietary delivery platform [1][3] - The company will present at the H.C. Wainwright Global Investment Conference from September 8-10, 2025, with a specific presentation scheduled for September 8 at 12:00 PM ET [1][2] Company Overview - Vaxart's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [3] - The company is developing oral vaccines for various diseases, including coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV) [3] - Vaxart has filed broad domestic and international patent applications for its proprietary technology related to oral vaccination using adenovirus and TLR3 agonists [3]

Company Overview - Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [4]. - The company aims to create vaccines that can be administered in pill form, which can be stored and shipped without refrigeration, thus eliminating the risk of needle-stick injuries [4]. Trading Transition - Vaxart, Inc. has transitioned from trading on NASDAQ to the OTCQX® Best Market, now trading under the symbol "VXRT" [1][2]. - The OTCQX Market provides companies with efficient and cost-effective access to U.S. capital markets, with streamlined requirements designed to lower the cost and complexity of being publicly traded [3]. Development Programs - Vaxart's current development programs include oral vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [4]. - The company has filed broad domestic and international patent applications for its proprietary technology related to oral vaccination using adenovirus and TLR3 agonists [4]. Market Position - OTC Markets Group Inc. operates regulated markets for trading 12,000 U.S. and international securities, with a focus on data-driven disclosure standards [5]. - The OTCQX Best Market is one of the four markets operated by OTC Markets Group, which also includes OTCQB® Venture Market, OTCID™️ Basic Market, and Pink Limited Market [5].

Core Points - Vaxart, Inc. will present at the Citizens Life Sciences conference on May 7-8, 2025 [1] - The presentation is scheduled for May 7 at 1:00 PM ET, with a live webcast available on the company's website [2] - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [3] Company Overview - Vaxart's vaccines are designed to be administered in pill form, which can be stored and shipped without refrigeration, reducing the risk of needle-stick injuries [3] - The company is developing oral vaccines for coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV) [3] - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology using adenovirus and TLR3 agonists [3]